News & Videos - ORIC PHARMACEUTICALS INC.

You are currently viewing all stock exchange news of the financial instrument ORIC PHARMACEUTICALS INC. regarding all markets in all languages.

> News03/07/2025 - 21:30 GlobeNewsWire published a news.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 03/07/2025 - 21:30• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 3, 2025 (the “Grant Date”), ORIC granted a total of 26,450 non-qualified stock options and 4,300 restricted stock units to three new non-executive employees who began their employment with ORIC in February 2025. These inducement...

Thank you Chart

> News02/25/2025 - 21:15 GlobeNewsWire published a news.

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones 02/25/2025 - 21:15• • GlobeNewsWire • Stocks

Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC expected in 1H 2026; ORIC-114 registrational development plans to focus on 1L NSCLC with anticipated initiation in 2026 Favorable enrollment across both programs allows for accelerated/augmented corporate milestones, including combination dose escalation data in mCRPC expected in 1H...

Thank you Chart

> News02/18/2025 - 21:05 GlobeNewsWire published a news.

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates 02/18/2025 - 21:05• • GlobeNewsWire • Stocks

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the...

Thank you Chart

> News02/07/2025 - 21:30 GlobeNewsWire published a news.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 02/07/2025 - 21:30• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 3, 2025 (the “Grant Date”), ORIC granted a total of 29,600 non-qualified stock options and 4,800 restricted stock units to two new non-executive employees who began their employment with ORIC in January 2025. These inducement...

Thank you Chart

> News01/27/2025 - 21:15 GlobeNewsWire published a news.

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences 01/27/2025 - 21:15• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February: Jones Research Precision Medicine Day – Participating in a fireside chat on Monday, February 3, 2025, at 12:30 p.m. ET Guggenheim Securities SMID Cap Biotech...

Thank you Chart

> News01/13/2025 - 13:05 GlobeNewsWire published a news.

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones 01/13/2025 - 13:05• • GlobeNewsWire • Stocks

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months,...

Thank you Chart

> News01/13/2025 - 13:00 GlobeNewsWire published a news.

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations 01/13/2025 - 13:00• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company has entered into a supply agreement with Janssen Research & Development, LLC, a Johnson & Johnson company, to evaluate ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, in combination with...

Thank you Chart

> News01/06/2025 - 21:15 GlobeNewsWire published a news.

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference 01/06/2025 - 21:15• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. PT. A live webcast of the company presentation will be available...

Thank you Chart

> News01/03/2025 - 21:30 GlobeNewsWire published a news.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 01/03/2025 - 21:30• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on January 2, 2025 (the “Grant Date”), ORIC granted a total of 16,400 non-qualified stock options and 2,800 restricted stock units to one new non-executive employee who began their employment with ORIC in December 2024. These inducement...

Thank you Chart

> News11/25/2024 - 21:15 GlobeNewsWire published a news.

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences 11/25/2024 - 21:15• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in December: 7 th Annual Evercore HEALTHCONx Conference – Participating in a fireside chat on Wednesday, December 4, 2024, at 2:35 p.m. ET Citi’s 2024 Global Healthcare Conference...

Thank you Chart

> News11/12/2024 - 21:05 GlobeNewsWire published a news.

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates 11/12/2024 - 21:05• • GlobeNewsWire • Stocks

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC-944 in combination with AR inhibitors for the treatment of prostate cancer Cash and investments of $282.4 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO,...

Thank you Chart

> News11/04/2024 - 21:15 GlobeNewsWire published a news.

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences 11/04/2024 - 21:15• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November: Guggenheim’s Inaugural Healthcare Innovation Conference – Participating in a fireside chat on Monday, November 11, 2024, at 10:30 a.m. ET Jefferies London...

Thank you Chart

> News11/01/2024 - 20:30 GlobeNewsWire published a news.

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 11/01/2024 - 20:30• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2024 (the “Grant Date”), ORIC granted a total of 61,800 non-qualified stock options and 10,400 restricted stock units to two new non-executive employees who began their employment with ORIC in October 2024. These inducement...

Thank you Chart

> News10/23/2024 - 11:00 GlobeNewsWire published a news.

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 10/23/2024 - 11:00• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the company presented a poster highlighting certain best-in-class properties of ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, to treat EGFR exon 20 insertions and other atypical mutations at the...

Thank you Chart

> News10/09/2024 - 20:15 GlobeNewsWire published a news.

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 10/09/2024 - 20:15• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 23-25, 2024, in Barcelona, Spain. Poster presentation details: Title: ORIC-114, a highly selective, brain...

Thank you Chart

> News10/04/2024 - 20:30 GlobeNewsWire published a news.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 10/04/2024 - 20:30• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2024 (the “Grant Date”), ORIC granted a total of 92,400 non-qualified stock options and 16,300 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2024. These...

Thank you Chart

> News09/06/2024 - 20:30 GlobeNewsWire published a news.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 09/06/2024 - 20:30• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024. These...

Thank you Chart

> News08/26/2024 - 20:05 GlobeNewsWire published a news.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences 08/26/2024 - 20:05• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference – Participating in a fireside chat on Thursday, September 5, 2024, at 8:00 a.m. ET Baird 2024 Global Healthcare...

Thank you Chart

> News08/12/2024 - 20:05 GlobeNewsWire published a news.

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates 08/12/2024 - 20:05• • GlobeNewsWire • Stocks

Initiated dosing of ORIC-944 in combinations with NUBEQA ® (darolutamide) and ERLEADA ® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combination with NUBEQA ® and in combination with ERLEADA ® Expanded leadership team with the appointment of industry veteran Keith Lui as Senior Vice President of Commercial and Medical Affairs...

Thank you Chart

> News08/05/2024 - 20:15 GlobeNewsWire published a news.

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs 08/05/2024 - 20:15• • GlobeNewsWire • Stocks

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs. “We are thrilled to welcome Keith to the ORIC leadership team,” said Jacob M. Chacko, M.D., president and chief executive officer. “Keith’s...

Thank you Chart